YU25703A - Mutanti hemokina u lečenju multiple skleroze - Google Patents
Mutanti hemokina u lečenju multiple sklerozeInfo
- Publication number
- YU25703A YU25703A YU25703A YUP25703A YU25703A YU 25703 A YU25703 A YU 25703A YU 25703 A YU25703 A YU 25703A YU P25703 A YUP25703 A YU P25703A YU 25703 A YU25703 A YU 25703A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- treatment
- multiple sclerosis
- mutants
- chemokines
- chemokine mutants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mutanti CC hemokina, koji sadrže najmanje dve mutacije na katjonskom mestu petlje 40-49 i koji, u odnosu na divlji tip molekula, imaju smanjenu aktivnost vezivanja za GAG. Pre svega, utvrđeno je da su takvi mutirani hemokini efikasni za lečenje multiple skleroze i/ili drugih demijelinizirajućih bolesti. Trostruki mutant RANTES je jedinjenje koje je dalo najbolje rezultate.[Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild- type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or other demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00121665 | 2000-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU25703A true YU25703A (sh) | 2006-05-25 |
| RS50738B RS50738B (sr) | 2010-08-31 |
Family
ID=8170011
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7402303B2 (sh) |
| EP (1) | EP1326628B1 (sh) |
| JP (1) | JP3908165B2 (sh) |
| KR (1) | KR100837898B1 (sh) |
| CN (1) | CN1285381C (sh) |
| AR (1) | AR030854A1 (sh) |
| AT (1) | ATE265222T1 (sh) |
| AU (2) | AU2002215919B2 (sh) |
| BG (1) | BG66137B1 (sh) |
| BR (1) | BR0114407A (sh) |
| CA (1) | CA2423616C (sh) |
| CZ (1) | CZ303409B6 (sh) |
| DE (1) | DE60103078T2 (sh) |
| DK (1) | DK1326628T3 (sh) |
| EA (1) | EA006137B1 (sh) |
| EE (1) | EE05174B1 (sh) |
| ES (1) | ES2217199T3 (sh) |
| HK (1) | HK1062811A1 (sh) |
| HR (1) | HRP20030215B1 (sh) |
| HU (1) | HUP0302194A3 (sh) |
| IL (2) | IL155178A0 (sh) |
| MX (1) | MXPA03003008A (sh) |
| NO (1) | NO330278B1 (sh) |
| PL (1) | PL204231B1 (sh) |
| PT (1) | PT1326628E (sh) |
| RS (1) | RS50738B (sh) |
| SI (1) | SI1326628T1 (sh) |
| SK (1) | SK287523B6 (sh) |
| UA (1) | UA77950C2 (sh) |
| WO (1) | WO2002028419A2 (sh) |
| ZA (1) | ZA200302315B (sh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005525089A (ja) | 2001-12-17 | 2005-08-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 |
| DE60303929T2 (de) * | 2002-04-04 | 2006-08-10 | Applied Research Systems Ars Holding N.V. | Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit |
| WO2004062688A2 (en) * | 2002-12-23 | 2004-07-29 | Applied Research Systems Ars Holding N.V. | Use of cc-chemokine mutants against liver diseases |
| DE602004018014D1 (de) * | 2003-10-22 | 2009-01-08 | Serono Lab | Cxcl8-antagonisten |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| DE60304435T2 (de) * | 2004-01-19 | 2006-08-24 | Ares Trading S.A. | Verfahren zur Reinigung von in Bakterien exprimierten Proteinen |
| GB0412400D0 (en) * | 2004-06-03 | 2004-07-07 | Univ Newcastle | Treatment of inflammatory conditions |
| EP1760110B1 (en) * | 2005-09-03 | 2011-11-02 | Samsung SDI Co., Ltd. | Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane |
| GB0614755D0 (en) | 2006-07-25 | 2006-09-06 | Univ Geneve | Cytokine derivatives |
| MX2010001307A (es) | 2007-08-02 | 2010-07-30 | Novimmune Sa | Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. |
| AU2011213559B2 (en) * | 2010-02-08 | 2015-05-07 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same |
| CA3101052A1 (en) | 2018-05-28 | 2019-12-05 | ORION Biotechnology Switzerland Sarl | Methods of inhibiting cerebral inflammation |
| WO2022093857A1 (en) * | 2020-10-26 | 2022-05-05 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
| WO1998006751A1 (en) * | 1996-08-16 | 1998-02-19 | Research Corporation Technologies, Inc. | Mcp-3, rantes and mip-1alpha receptor antagonists |
| EP0906954A1 (en) * | 1997-09-29 | 1999-04-07 | Applied Research Systems ARS Holding N.V. | Amino-terminal truncated c-c chemokines as chemokine antagonist |
| DE69832216T2 (de) * | 1997-12-23 | 2006-05-24 | Fondazione Centro San Raffaele Del Monte Tabor | RANTES-Mutanten und therapeutische Anwendungen davon |
| AU2740900A (en) * | 1999-01-29 | 2000-08-18 | Millennium Pharmaceuticals, Inc. | Method of treating demyelinating inflammatory disease using ccr1 antagonists |
-
2001
- 2001-03-10 UA UA2003044038A patent/UA77950C2/uk unknown
- 2001-10-03 AT AT01986265T patent/ATE265222T1/de active
- 2001-10-03 PT PT01986265T patent/PT1326628E/pt unknown
- 2001-10-03 PL PL362350A patent/PL204231B1/pl not_active IP Right Cessation
- 2001-10-03 AU AU2002215919A patent/AU2002215919B2/en not_active Ceased
- 2001-10-03 KR KR1020037004599A patent/KR100837898B1/ko not_active IP Right Cessation
- 2001-10-03 EP EP01986265A patent/EP1326628B1/en not_active Expired - Lifetime
- 2001-10-03 WO PCT/EP2001/011428 patent/WO2002028419A2/en active IP Right Grant
- 2001-10-03 EA EA200300439A patent/EA006137B1/ru not_active IP Right Cessation
- 2001-10-03 HU HU0302194A patent/HUP0302194A3/hu unknown
- 2001-10-03 CA CA2423616A patent/CA2423616C/en not_active Expired - Fee Related
- 2001-10-03 DK DK01986265T patent/DK1326628T3/da active
- 2001-10-03 MX MXPA03003008A patent/MXPA03003008A/es active IP Right Grant
- 2001-10-03 EE EEP200300139A patent/EE05174B1/xx not_active IP Right Cessation
- 2001-10-03 ES ES01986265T patent/ES2217199T3/es not_active Expired - Lifetime
- 2001-10-03 ZA ZA200302315A patent/ZA200302315B/en unknown
- 2001-10-03 DE DE60103078T patent/DE60103078T2/de not_active Expired - Lifetime
- 2001-10-03 JP JP2002532243A patent/JP3908165B2/ja not_active Expired - Fee Related
- 2001-10-03 BR BR0114407-3A patent/BR0114407A/pt not_active IP Right Cessation
- 2001-10-03 AU AU1591902A patent/AU1591902A/xx active Pending
- 2001-10-03 CN CNB018199178A patent/CN1285381C/zh not_active Expired - Fee Related
- 2001-10-03 CZ CZ20030947A patent/CZ303409B6/cs not_active IP Right Cessation
- 2001-10-03 US US10/398,457 patent/US7402303B2/en not_active Expired - Fee Related
- 2001-10-03 SK SK406-2003A patent/SK287523B6/sk not_active IP Right Cessation
- 2001-10-03 RS YUP-257/03A patent/RS50738B/sr unknown
- 2001-10-03 SI SI200130130T patent/SI1326628T1/xx unknown
- 2001-10-03 IL IL15517801A patent/IL155178A0/xx unknown
- 2001-10-04 AR ARP010104684A patent/AR030854A1/es unknown
-
2003
- 2003-03-20 HR HR20030215A patent/HRP20030215B1/xx not_active IP Right Cessation
- 2003-03-28 BG BG107685A patent/BG66137B1/bg unknown
- 2003-04-01 IL IL155178A patent/IL155178A/en not_active IP Right Cessation
- 2003-04-03 NO NO20031525A patent/NO330278B1/no not_active IP Right Cessation
-
2004
- 2004-08-02 HK HK04105657A patent/HK1062811A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU25703A (sh) | Mutanti hemokina u lečenju multiple skleroze | |
| IL214607A0 (en) | 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| CA2257133A1 (en) | Human dnase i hyperactive variants | |
| CA2000786A1 (en) | 3-piperidinyl-1,2-benzisoxazoles | |
| IL119461A (en) | 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines | |
| WO2005016893A3 (en) | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases | |
| HU9302613D0 (en) | Process for producing (s)-(+)-hydroxi-chloro quine | |
| MX9604145A (es) | Metodos y composiciones utiles para la inhibicion de angiogenesis. | |
| CA2151674A1 (en) | Methods of Administering CRF Antagonists | |
| PL354482A1 (en) | Flexible brush comprising a mixture of polymers | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| NO20012249L (no) | Faststoffsammensetning inneholdende D-mannitol og cerivastatin samt anvendelse av faststoffsammensetning forfremstilling av farmasöytisk preparat | |
| YU67900A (sh) | Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima | |
| AU6682594A (en) | Treatment of septic shock | |
| CA2008390A1 (en) | Mutants of human antithrombin iii | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| IL162600A0 (en) | Cc-chemokine mutants as cc-chemokine antagonists | |
| AU6234099A (en) | Gene therapy of alzheimer's disease by delivery of an encoded apoliprotein | |
| EP1431391A3 (en) | Rantes mutants and therapeutic applications thereof | |
| GB2277265B (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema | |
| CA2260863A1 (en) | Treatment of psychotic disorders | |
| HUP9802536A3 (en) | Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer | |
| ZA924128B (en) | New combination preparations for treatment of Parkinson's disease. | |
| HUP0004599A2 (hu) | Gonadotropinok expresszáltatása Dictyosteliumban |